APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology

Recent evidence supports a link between increased TDP‐43 burden and the presence of an APOE4 gene allele in Alzheimer's disease (AD); however, it is difficult to conclude the direct effect of APOE on TDP‐43 pathology due to the presence of mixed AD pathologies. The goal of this study is to address how APOE isoforms impact TDP‐43 pathology and related neurodegeneration in the absence of typical AD pathologies.

[1]  David J. Calkins,et al.  Solving neurodegeneration: common mechanisms and strategies for new treatments , 2022, Molecular Neurodegeneration.

[2]  P. van Damme,et al.  The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD , 2022, Molecular neurodegeneration.

[3]  G. Sobue,et al.  Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. , 2022, Brain : a journal of neurology.

[4]  D. Bosco,et al.  Microglial TREM2 in amyotrophic lateral sclerosis , 2021, Developmental neurobiology.

[5]  D. Dickson,et al.  TDP-43 Pathology in Alzheimer’s Disease , 2021, Molecular neurodegeneration.

[6]  D. Dickson,et al.  Concurrent tau pathologies in frontotemporal lobar degeneration with TDP‐43 pathology , 2021, bioRxiv.

[7]  L. Petrucelli,et al.  Cellular and pathological heterogeneity of primary tauopathies , 2021, Molecular neurodegeneration.

[8]  Tau En Lim,et al.  Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease , 2021, Molecular neurodegeneration.

[9]  Timothy J. Hohman,et al.  Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions , 2021, Molecular Neurodegeneration.

[10]  F. Svensson,et al.  TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation , 2021, Molecular Neurodegeneration.

[11]  M. Mattson,et al.  TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration , 2021, bioRxiv.

[12]  G. Bu,et al.  APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease , 2020, Molecular Neurodegeneration.

[13]  M. Selenica,et al.  TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model , 2020, Journal of neuroinflammation.

[14]  T. Goldberg,et al.  Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies , 2020, Nature Communications.

[15]  Michelle K. Cahill,et al.  Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency , 2020, Nature.

[16]  Maxime W. C. Rousseaux,et al.  The role of TDP-43 mislocalization in amyotrophic lateral sclerosis , 2020, Molecular Neurodegeneration.

[17]  Huaxi Xu,et al.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease , 2020, Molecular Neurodegeneration.

[18]  Y. Asmann,et al.  Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways , 2020, Neuron.

[19]  J. Grutzendler,et al.  TREM2: Modulator of Lipid Metabolism in Microglia , 2020, Neuron.

[20]  Y. Asmann,et al.  APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid , 2020, Science Translational Medicine.

[21]  D. Markusic,et al.  Immune Response Mechanisms against AAV Vectors in Animal Models , 2019, Molecular therapy. Methods & clinical development.

[22]  G. Bu,et al.  Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies , 2019, Nature Reviews Neurology.

[23]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[24]  C. Jack,et al.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.

[25]  D. Fardo,et al.  Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy , 2019, Laboratory Investigation.

[26]  D. Dickson,et al.  TDP‐43 pathology in multiple system atrophy: colocalization of TDP‐43 and α‐synuclein in glial cytoplasmic inclusions , 2018, Neuropathology and applied neurobiology.

[27]  P. Schulz,et al.  Disease-modifying effects of metabolic perturbations in ALS/FTLD , 2018, Molecular neurodegeneration.

[28]  L. Petrucelli,et al.  Association of Apolipoprotein E &egr;4 With Transactive Response DNA-Binding Protein 43 , 2018, JAMA neurology.

[29]  Charles C. White,et al.  Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study , 2018, The Lancet Neurology.

[30]  B. Boeve,et al.  Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype , 2018, Acta Neuropathologica.

[31]  John L. Robinson,et al.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.

[32]  G. Bu,et al.  Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease , 2018, Biological Psychiatry.

[33]  A. Chen-Plotkin,et al.  Genetic Modifiers in Neurodegeneration , 2018, Current Genetic Medicine Reports.

[34]  J. Trojanowski,et al.  Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy , 2018, Nature Neuroscience.

[35]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[36]  A. Goate,et al.  A Tale of Two Genes: Microglial Apoe and Trem2. , 2017, Immunity.

[37]  John L. Robinson,et al.  Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration , 2017, Acta neuropathologica communications.

[38]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[39]  J. Hardy,et al.  Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia , 2017, Brain : a journal of neurology.

[40]  D. Holtzman,et al.  Elucidating the Role of TREM2 in Alzheimer’s Disease , 2017, Neuron.

[41]  Wenzhang Wang,et al.  Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  A. Chiò,et al.  The Role of APOE in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. , 2016, JAMA neurology.

[43]  Sara Zarei,et al.  A comprehensive review of amyotrophic lateral sclerosis , 2015, Surgical neurology international.

[44]  R. Klein,et al.  AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats , 2015, Molecular therapy. Methods & clinical development.

[45]  S. Younkin,et al.  Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)* , 2015, The Journal of Biological Chemistry.

[46]  M. Farzan,et al.  The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E* , 2015, The Journal of Biological Chemistry.

[47]  J. Trojanowski,et al.  Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 , 2015, Acta Neuropathologica.

[48]  S. Murayama,et al.  Incidence and extent of TDP-43 accumulation in aging human brain , 2015, Acta neuropathologica communications.

[49]  Murray Grossman,et al.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine , 2015, Acta Neuropathologica.

[50]  C. Jack,et al.  TDP-43 is a key player in the clinical features associated with Alzheimer’s disease , 2014, Acta Neuropathologica.

[51]  L. Pinessi,et al.  Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta-analysis , 2013, Alzheimer's & Dementia.

[52]  D. Burns,et al.  TDP-43, an ALS Linked Protein, Regulates Fat Deposition and Glucose Homeostasis , 2013, PloS one.

[53]  Jianbin Tong,et al.  Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. , 2012, The Journal of clinical investigation.

[54]  Charles D. Smith,et al.  Hippocampal sclerosis in advanced age: clinical and pathological features. , 2011, Brain : a journal of neurology.

[55]  Jernej Ule,et al.  TDP‐43 regulates its mRNA levels through a negative feedback loop , 2011, The EMBO journal.

[56]  D. Price,et al.  Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism , 2010, Proceedings of the National Academy of Sciences.

[57]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[58]  J. Trojanowski,et al.  Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies , 2008, Journal of neuropathology and experimental neurology.

[59]  D. Dickson,et al.  TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease , 2007, Annals of neurology.

[60]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[61]  Jennifer Farmer,et al.  Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.

[62]  B. Dubois,et al.  Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis , 2002, European Journal of Human Genetics.